Primary Membranous Nephropathy. Nephrotic syndrome with diffuse membranous glomerulonephritis
Conditions
Interventions
Intervention 1: Intervention group: Intravenous cyclophosphamide 500mg/m2 on 2, 4 and 6 months. Injection Cyclophosphamide wil be given as infusion of 100 ml saline over 1 hour. Before infusion patien
Sponsors
Jinnah Hospital/ Allama Iqbal Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Serum Anti-Phospho Lipase A2 Receptor positive or IgG4 positivity on Immunofluorescence. Biopsy –proven Idiopathic Membranous Nephropathy, moderate risk group (Spot Urine protein/ spot urine creatinine Ratio between 4 to 8 g/g) that has failed to respond to conservative therapy for 6 months. Biopsy–proven Idiopathic Membtanous Nephropathy high risk group (Spot Urine protein/ spot urine creatinine Ratio more than 8g/g).
Exclusion criteria
Exclusion criteria: Patients with clinical, histologic, or serologic evidence of secondary Membranous Nephropathy. Evidence of Hepatitis B/C and Human Immunodeficiency Virus Evidence of malignancy (Prostate Specific Antigen, Mammogram, Chest x-ray.) Active or ongoing infection/ Recent infection. Allergy to cyclophosphamide. Contraindication to steroid/ cyclophosphamide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in proteinuria calculated by spot urine protein: creatinine ratio less than 0.2. Timepoint: Monthly for 6 months after starting treatment, then monthly follow up after 6 months of completion of treatment. Total 12 months. Method of measurement: Spot urine sample will be send to lab. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin. Timepoint: Monthly for 6 months after starting treatment (duration of treatment 6 months), then monthly follow up after 6 months of completion of treatment. Total 12 months. Method of measurement: Blood sample.;White cell count. Timepoint: Monthly for 6 months after starting treatment (duration of treatment 6 months), then monthly follow up after 6 months of completion of treatment. Total 12 months. Method of measurement: Blood sample.;Reduction in Serum Creatinine. Timepoint: Monthly for 6 months after starting treatment (duration of treatment 6 months), then monthly follow up after 6 months of completion of treatment. Total 12 months. Method of measurement: Blood sample. | — |
Countries
Pakistan
Contacts
Public ContactDr Muhammad Saleem
Jinnah Hospital/ Allama Iqbal Medical College
Outcome results
None listed